Aiosyn launched a new website built around quantitative AI-based tissue analysis for preclinical studies and automated quality control for clinical laboratories.
Published
Signal category
Products & Services
Quote
“We are happy to launch the new Aiosyn website, built around our key areas: quantitative AI-based tissue analysis for preclinical studies and automated quality control for clinical laboratories.”
— Aiosyn team
Company
Aiosyn
Achieve more perspective through precision pathology
- Industry
- Medical Equipment Manufacturing
- Location
- Nijmegen, NL
- Company size
- 8 employees
Aiosyn is a Dutch healthtech company delivering AI-powered precision pathology solutions to enhance diagnosis and accelerate research in breast cancer and chronic kidney disease. Our algorithms integrate with existing digital pathology software and can be deployed via cloud-based or on-premise installations, ensuring adaptability to diverse laboratory environments. We support digital pathology labs with automated slide quality control (QC) and offer the first IVDR-certified AI solution for mitotic figure counting, improving consistency and efficiency in breast cancer grading. Our NephroPath platform enables quantitative kidney biomarker analysis for CROs and biopharma, helping streamline and scale (pre-)clinical drug development.
Founded 2021